Genfit SA
F:XUP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
G
|
Genfit SA
F:XUP
|
FR |
|
A
|
American Software Inc
XBER:ADWA
|
US |
|
Wipro Ltd
NYSE:WIT
|
IN |
|
Japfa Comfeed Indonesia Tbk PT
IDX:JPFA
|
ID |
|
N
|
Nike Inc
XHAM:NKE
|
US |
|
Kongsberg Gruppen ASA
F:KOZ0
|
NO |
|
G
|
Gold Road Resources Ltd
XBER:E6Q
|
AU |
|
Enova International Inc
NYSE:ENVA
|
US |
|
P
|
Pinnacle Financial Partners Inc
F:PFZ
|
US |
Genfit SA
Genfit SA is a biopharmaceutical company that develops medicines and diagnostic tools for liver diseases. Its main work has focused on conditions such as metabolic dysfunction-associated steatohepatitis, or MASH, and other serious liver disorders where doctors need better ways to identify patients and slow disease progression. The company does not sell a broad consumer product line; it builds drug candidates and disease tests for use in specialist medical settings. Genfit makes money mainly by advancing its own drug programs, licensing technology, and working with partners in drug development and diagnostics. In this kind of business, value comes from turning research into approved treatments or validated tests that can be sold to hospitals, labs, or pharmaceutical partners. It may also earn fees or milestone payments when partners use its intellectual property or help develop a product. What makes Genfit's business model different is that it sits at the point where liver disease research meets patient care. Many biotech companies focus only on drugs, but Genfit has also built expertise in diagnostic testing, which can help find the right patients for treatment and support clinical trials. That gives the company a role in both detecting disease and developing therapies for it.
Genfit SA is a biopharmaceutical company that develops medicines and diagnostic tools for liver diseases. Its main work has focused on conditions such as metabolic dysfunction-associated steatohepatitis, or MASH, and other serious liver disorders where doctors need better ways to identify patients and slow disease progression. The company does not sell a broad consumer product line; it builds drug candidates and disease tests for use in specialist medical settings.
Genfit makes money mainly by advancing its own drug programs, licensing technology, and working with partners in drug development and diagnostics. In this kind of business, value comes from turning research into approved treatments or validated tests that can be sold to hospitals, labs, or pharmaceutical partners. It may also earn fees or milestone payments when partners use its intellectual property or help develop a product.
What makes Genfit's business model different is that it sits at the point where liver disease research meets patient care. Many biotech companies focus only on drugs, but Genfit has also built expertise in diagnostic testing, which can help find the right patients for treatment and support clinical trials. That gives the company a role in both detecting disease and developing therapies for it.
